PTC CLINIC
Informace pro odborníky

Odborné publikace PTC maligní lymfomy

1. Tseng, Y., Stevenson, P., Nguyen, B., Li, D., Lee, D., Paydar, I., Nakashima, J., Balogh, A., Ravella, R., Barbour, A., Post, C., Ababneh, H., Pinnix, C., Ballas, L., Binkley, M., Dedeckova, K., Hoppe, R., Patel, C., Nabavizadeh, N., Kelsey, C., Kumar, K., Landsburg, D., Figura, N., Lo, A., Plastaras, J. Impact of Myc-Altered Pathology on Radiation Therapy Efficacy Among Patients With Relapsed/Refractory Large-B Cell Lymphoma: A Collaborative Study by ILROG. International Journal of Radiation Oncology, Biology, Physics. Volume 121, Issue 5, 1 April 2025, Pages 1237-1247. doi.org/10.1016/j.ijrobp.2024.11.072.
2. Michnova K. Protonová radioterapie maligního lymfomu založená na důkazech. Transfuze a hematologie dnes. 2/2024.
3. Ntentas, G., Dedeckova, K., Andrlik, M., Aznar, M., Shakir, R., Ramroth, J., Begum, R., Kubes, J., Darby, S., Mikhaeel, N., Cutter, D. Proton Therapy in Supradiaphramatic Lymphoma: Predicting Treatment-Related Mortality to Help Optimize Patient Selection. Int J Radiation Oncol Biol Phys, Vol. 112, No. 4, pp. 913−925, 2022. doi.org/10.1016/j.ijrobp.2021.10.151
4. Ntentas G, Dedeckova K, Andrlik M, Aznar MC, Shakir R, Ramroth J, Begum R, Kubeš J, Darby SC, Mikhaeel NG, Cutter DJ. Proton Therapy in Supradiaphragmatic Lymphoma: Predicting Treatment-Related Mortality to Help Optimize Patient Selection.Int J Radiat Oncol Biol Phys. 2022 Mar 15;112(4):913-925. doi: 10.1016/j.ijrobp.2021.10.151. Epub 2021 Nov 9. PMID: 34762970; PMCID: PMC8865523.
5. Tseng YD, Hoppe BS, Dedeckova K, Patel CG, Hill-Kayser CE, Miller DM, Maity A, Mendenhall NP, Mailhot Vega RB, Yock TI, Baliga S, Hess CB, Winkfield KM, Mohindra P, Rosen LR, Tsai H, Chang J, Hartsell WF, Plastaras JP. Risk of Pneumonitis and Outcomes After Mediastinal Proton Therapy for Relepsed/Refractory Lymphoma: A PTCOG and PCG Collaboration. Int J Radiat Oncol Biol Phys. 2021 Jan 1;109(1): 220-230. doi: https://doi.org/10.1016/j.ijrobp.2020.08.055.
6. Ntentas, G., Dedeckova, K., Andrlik, M., Aznar, M. C., George, B., Kubeš, J., Darby, S. C., Cutter, D. J.. Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma – Which Patients Benefit the Most.Practical Radiation Oncology (2019) 9, 179-187. DOI: 10.1016/j.prro.2019.01.006
7. Shbib Dabaja, B., Hoppe, B., Plastaras, J., Newhauser, W., Rosolova, K., Flamour, S., Mohan, R., Mikhaeel, G., Kirova, Y., Specht, L., Yahalom, J. (2018). Proton therapy for adults with mediastinal lymphomas: the international lymphoma radiation oncology group (ilrog) guidelines.Blood.2018.https://doi.org/10.1182/blood-2018-03-837633
8. Ntentas, G., Dědečková K., Andrlik, M., Aznar, M.C., George, B., Darby, S.C., Cutter, D. (2017). Predicted cardiac and second cancer risks in hodgkin lymphoma patients treated with advanced proton beam therapy compared to photon radiation therapy. S181 ASTRO Annual Metting  International Journal of Radiation Oncology, Biology, Physics, 99(2). 2017. doi: https://doi.org/10.1016/j.ijrobp.2017.06.454.
9. Tseng, Y., Cutter, D., Plastaras, J., Parikh, R., Cahlon, O., Chuong, M., Dedeckova, K., Khan, M., Lin, S., McGee, L., Shen, E., Terezakis, S., Badiyan, S., Kirova, Y., Hoppe, R., Mendenhall, N., Pankuch, M., Flampouri, S., Ricardi, U., Hoppe, B. Evidence-based Review on the Use of Proton Therapy in Lymphoma From the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee. International Journal of Radiation.Oncology*Biology*Physics [online]. 2017, 99(4), 825-842 [cit. 2018-10-26]. ISSN 03603016. http://dx.doi.org/10.1016/j.ijrobp.2017.05.004
10. Tseng, Y. D., Cutter, D. J., Plastaras, J. P., Parikh, R. R., Cahlon, O., Chuong, M. D., Dedeckova, K., Khan, M. K., Lin, S.-Y., McGee, L. A., Shen, E. Y.-L., Terezakis, S. A., Badiyan, S. N., Kirova, Y. M., Hoppe, R. T., Mendenhall, N. P., Pankuch, M., Flampouri, S., Ricardi, U., Hoppe, B. S. Evidence-based Review on the Use of Proton Therapy in Lymphoma From the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee.International Journal for Radiation Oncology, Biology, Physics. (2017) Nov 15; 99(4):825-842. doi: 10.1016/j.ijrobp.2017.05.004. Epub 2017 Sep 21.
11. Kubeš, J., Vítek, P., Dědečková, K., Ondrová, B. (2014). Velmi pozdní následky radioterapie – limitující faktor současných radioterapeutických technik (Very late side effects of radiotherapy – limiting factor of current radiotherapeutic techniques). Klinicka onkologie Journal, 27(3), 161-165. doi: 14735/amko2014161.
12. Dědečková K, Móciková H, Belada D, Janíková A, Dolečková M, Malinová B, Feltl D, Vošmik M, Svoboda T, Marková J, Trněný M. (2013). The role of radiotherapy in the treatment of malignant lymphomas – recommendations of the Czech Lymphoma Study Group. Klinicka onkologie Journal, 26(2), 99-109. Retrieved from  PubMed PMID: 23718668. DOI: 10.14735/amko201399
13. Dědečková, K., Móciková, H., Belada, D., Obořilová-Janíková, A., Dolečková, M., Malinová, B., Feltl, D., Vošmik, M., Svoboda, T., Marková, J., Trněný, M.(2013). Postavení radioterapie v léčbě maligních lymfomů – doporučení Kooperativní lymfomové skupiny. Klinicka onkologie Journal, 26(2), 99-109. doi: 14735/amko201399.
14. Marková J., Kahraman D., Kobe C., Skopalová M., Móciková H., Klásková K., Dědečková, , Eich H.T., Böll B., Dietlein M., Kozák T. (2012). Role of (18F)-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, Adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone. Leukemia & Lymphoma, 53(1), 64-70. doi: 10.3109/10428194.2011.603444.
15. Chocenská, E., Móciková, H., Dědečková K. (2010). Průvodce pacienta onkologickou léčbou (Patient’s Guide to Cancer Treatment).https://www.linkos.cz/pacient-a-rodina/pomoc-v-nemoci/kde-hledat-informace/onkologicke-knihy/pruvodce-pacienta-onkologickou-lecbou/.
16. Marková J., Kobe C., Skopalová M., Klásková K., Dědečková, Plütschow A., Eich H.T., Dietlein M., Engert A., Kozák T. (2009). FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin’s lymphoma has a high negative predi. Annals of Oncology, (20)7. 1270-4. doi: 10.1093/annonc/mdn768.
17. Marková, J., Kobe C., Skopalová, M., Žikavská, L., Vernerová, Z., Klásková, K., Dědečková, K., Eich, H.T., Dietlein, M., Fuchs, M., Engert, A., Kozák, T. (2009). Early and late response assessment with fdg-pet after beacopp-based chemotherapy in advanced-stage Hodgkin lymphoma patients has a high negative predictive value. Haematologica, 94(2).
18. Markova, J., Kobe, C., Skopalova, M., Klaskova, K., Dedeckova, K., Plütschow, A., Eich, H., Dietlein, M., Engert, A., Kozak, T. FDG–PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin’s lymphoma has a high negative predictive value. Annals of Oncology [online]. 2009, 2009-7-01, 20(7), 1270-1274 [cit. 2018-10-26]. ISSN 1569-8041. doi:10.1093/annonc/mdn768

Výběr posterů na mezinárodních konferencích:

• PTCOG 63. Dědečková K., Andrlík M., Kaliská L., Kubeš J., Zapletalová S., Al-Hamami S., Ondrová B., Vondráček V., Navrátil M., Prausová J. Clinical experience with proton RT in patients with refractory or relapsed B-cell hematologic malignancies treated with CAR T-cell therapy
• 2023 4th ILROG Educational Conference
• 2020 LYMPHOM Poster Prazske hematologicke dny 2020
• 2019 LYMPHOM Poster Tokio ILROG Educational Symposium 2019
• Predicted Cardiac and Second Cancer Risks in Hodgkin Lymphoma Patients Treated With Advanced Proton Beam Therapy Compared to Photon Radiation Therapy Ntentas, G. , Dedeckova, K. et al. International Journal of Radiation Oncology • Biology • Physics , Volume 99 , Issue 2 , S181 ASTRO Annual Meeting, San Diego, 2017
• Pencil beam scanning proton therapy for lymphoma patients with mediastinal involvement: Prague´s single institution experience. K. Dedeckova, J. Stokucova, H. Mocikova, J. Markova, L. Gaherova, I. Kantorova, B. Ondrova, V. Vondracek, P. Vitek, J. Kubes.  PTCOG COnference, Prague 2016
• Pencil Beam Scanning Proton Therapy for Lymphoma Patients with Mediastinal Involvement: A Dosimetric Study and Preliminary Clinical Data. Authors: Katerina Dedeckova  13th International Conference on Malignant Lymphoma, 17-20 June 2015 Lugano
• Dedeckova, K., Stokucova J., Mocikova, H., Markova, J., Gaherova, L., Kantorova, I., Ondrova, B., Vondracek, V., Vitek, P., Kubes, J. (2016). Pencil beam scanning proton therapy for lymphoma patients with mediastinal involvement: Prague´s single institution experience. PTCOG Conference.
• Dedeckova K., Markova J., Gaherova, L., Kantorova, I., Ondrova, B., Vondracek, V., Vitek, P., Kubes, J. (2016). Proton radiotherapy for mediastinal Hodgkin lymphoma: single institution experience. 10th International Symposium on Hodgkin Lymphoma.
• Dedeckova, K., Mocikova, H., Markova, J., Gaherova, L., Koren, J., Backova, B., Vondracek, V., Sindelar, D., Kohlova, T., Ondrova, B., Kantorova, I., Vitek, P., Pytlik, R., Kubes, J. (2015). Pencil Beam Scanning Proton Therapy for Lymphoma Patients with Mediastinal Involvement: A Dosimetric Study and Preliminary Clinical Data. Hematological Oncology, 33, 191.